The newest version of the ASCO guidelines for lung cancer surveillance after curative lung cancer therapy is presented. The overall quality of supportive evidence is low, and the strength of recommendations is moderate. CT is recommended as the optimal imaging modality. Of interest, PET and circulating biomarkers are not recommended for routine surveillance.
You are here:
Lung Cancer Surveillance After Definitive Curative-Intent Therapy: ASCO Guideline
Submitted by: Mark Ferguson
Source: Journal of Clinical Oncology
Keywords:
Author(s): Bryan J. Schneider, Nofisat Ismaila, Joachim Aerts, Caroline Chiles, Megan E. Daly, Frank C. Detterbeck, Jason W.D. Hearn, Sharyn I. Katz, Natasha B. Leighl, Benjamin Levy, Bryan Meyers, Septimiu Murgu, Larissa Nekhlyudov, Edgardo S. Santos, Navneet Singh, Joan Tashbar, David Yankelevitz, and Nasser Altorki
